Navigation Links
Covance Reports Fourth Quarter Pro Forma Net Revenue Of $561 Million, Pro Forma EPS Of $0.73 And Adjusted Net Orders Of $769 Million
Date:1/24/2013

pment services, testing mix and geographic mix of kit receipts in central laboratories,  fluctuations in currency exchange rates, the realization of savings from the Company's announced restructuring actions, the cost and pace of completion of our information technology projects and the realization of benefits therefrom,  and other factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.  The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.

Financial Exhibits FollowCOVANCE INC.CONSOLIDATED INCOME STATEMENTSFOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2012 AND 2011(Dollars in thousands, except per share data)Three Months Ended December 31Years Ended December 312012201120122011(UNAUDITED)Net revenues$
562,180$
532,478$   2,180,621$   2,095,938Reimbursable out-of-pocket expenses46,96449,907185,138140,508Total revenues609,144582,3852,365,7592,236,446Costs and expenses:  Cost of revenue395,841371,8521,570,2231,467,051  Reimbursable out-of-pocket expenses46,96449,907185,138140,508  Selling, general and administrative92,82395,752358,854343,044  Depreciation and amortization30,42325,923117,708105,214  Goodwill impairment charge--17,959-Total costs and expenses566,051(a)543,434(c)2,249,882(b)2,055,817(d)Income from operations43,093(a)38,951(c)115,877(b)180,629(d)Other expense, net:  Interest expense, net1,1533393,5061,979  Foreign exchange transaction loss, net1733561,4741,248  Impairment of equity investment-12,1197,37312,119  Gain on sale of investment--(1,459)-  Loss on sale of business--169-Other expense, net1,32612,814(c)11,06315,346(d)Income before taxes and equity investee earnings41,767(a)26,137(c)104,814(b)165,283(d)Taxes on income7,870(a)5,172(c)10,099(b)33,574(d)
'/>"/>

SOURCE Covance Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Covance To Present At The William Blair 32nd Annual Growth Stock Conference
2. Covance Reports Second Quarter Pro Forma Net Revenue Of $538 Million, Pro Forma EPS Of $0.65 And Adjusted Net Orders Of $701 Million
3. Covance to Present at the Morgan Stanley Global Healthcare Conference
4. Covance Reports Third Quarter Pro Forma Net Revenue Of $542 Million, Pro Forma EPS Of $0.72 And Adjusted Net Orders Of $701 Million
5. Covance To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
6. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
7. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
8. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
9. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
10. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
11. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Shire plc (LSE: ... waived the Office of Fair Trading (OFT) approval condition to ... of ViroPharma Incorporated (NASDAQ: VPHM).   As a ... on OFT approval, and Shire expects to complete the tender ... time, subject to the satisfaction of all of the remaining ...
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... subsidiary, BreedIT Ltd., the exclusive worldwide distributor of highly ... announced that on January 7, 2014, the Company,s board ... Ben-Zion Weiner as its new member of ... Weiner held executive positions with Teva Pharmaceutical Industries Ltd ...
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented ... C. difficile and TB in ambulances and other transport vehicles, ... is now being used by rescue personnel for the first ... and transport patients from coming in contact with these deadly ... is the first in the nation to begin sanitizing the ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ... Insulin-PH20 (recombinant human insulin with rHuPH20) produced glycemic ... (mealtime) insulin analog. The overall safety and adverse ... and both treatments were well tolerated. Insulin-PH20 achieved ...
... HistoRx, Inc. (privately held), a diagnostics company, announced ... of clinical diagnostic assays based on AQUA® technology. ... specialized laboratory service provider, is launching NexCourse®(1) BCa ... assays based on quantitative immunohistochemistry.  NexCourse BCa by ...
Cached Medicine Technology:Halozyme's rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro 2Halozyme's rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro 3Halozyme's rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro 4Halozyme's rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro 5HistoRx Announces First Clinical Diagnostic Use of AQUA® Technology 2HistoRx Announces First Clinical Diagnostic Use of AQUA® Technology 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... , , , , ... (Nasdaq: WCRX ) today announced its results for the ... 30, 2009 increased 7.1% to $250.8 million over the prior year ... net sales of DORYX, LOESTRIN 24 FE and ESTRACE Cream which ...
... - Quarter Marked by Launch of RYZOLT(TM) in U.S. -, ... Novel Trazodone, ... , , LAVAL, QC, Aug. 7 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: ... figures are in Canadian dollars unless otherwise stated. , "The second quarter of 2009 was highlighted ...
... ... and technology solutions, today announced the opening of a Chicago field office to better support ... ... Marathon Health, a leading provider of onsite employee health services and technology solutions, ...
... ... vice president for consulting. , ... St. Louis, MO (Vocus) -- Navvis & Company announces the appointment ... the firm and its clients extensive experience and expertise in health system operations, strategic ...
... expensive patients need fewer health care resources and cost insurers ... care team that tracks their health and offers regular support, ... Bloomberg School of Public Health. The research, published in the ... the first eight months of a randomized controlled trial, patients ...
... , WASHINGTON, Aug. 6 Lung Cancer Alliance ... another $11.8 million of the $20 million lung cancer research ... Research Program (CDMRP). , , (Logo: ... The solicitation invited researchers to compete for $10.5 ...
Cached Medicine News:Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 18Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 2Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 3Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 4Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 5Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 6Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 7Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 8Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 9Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 10Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 11Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 12Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 13Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 14Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 15Health News:Marathon Health Expands Midwest Presence 2Health News:Cleveland Joins Navvis & Company 2Health News:Guided care reduces cost of health care for older persons with chronic conditions 2Health News:LCA Announces More Requests for Bids on Lung Cancer Research Programs Funded Through the Department of Defense 2
... System supports approaches to Admitting/Discharge/Transfer ... record keeping functions using a ... facilities and cut across institutional ... community clinics, physician, agency, nursing ...
... Dairylands Clinical Information Management ... suite of integrated applications ... departments and automate administrative ... The applications allow organizations ...
... include a Patient Face Sheet, ... many as six custom tabs, ... information is important for you ... Import Manager utility lets you ...
... WEBeDoctor® Physician-office® is an ... physicians, (Solo practice, group ... to complete their normal ... It is a front ...
Medicine Products: